ClinicalTrials.gg
CompletedNCT03530995Updated May 25, 2022Results posted

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

A Phase 1 interventional study of Belumosudil and Itraconazole in Drug-drug Interaction, Autoimmune Diseases and Fibrotic Disease, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.

Enrollment
40th of 65
73 · median 94
Started
2018
with 3 others
Phase 1
15 of 73
1 open now
Registered
30th of 73
by date

Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 40th largest by enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 1, and was the 30th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Autoimmune Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.

Read the detailed description

Part 1:

The primary objective of Part 1 of this study is to determine the effect of itraconazole, rifampicin, and rabeprazole on the pharmacokinetics of once daily (QD) orally administered belumosudil in healthy male subjects. Part 1 consists of 4 periods.

In each study period, subjects will receive a single dose of belumosudil, in the fed state. Additionally, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of perpetrator drugs in Periods 2 to 4; a strong CYP3A4 inhibitor, itraconazole, in Period 2; a proton pump inhibitor, rabeprazole, in Period 3; and a strong CYP3A4 inducer, rifampicin, in Period 4.

Subjects will receive a total of 4 single oral dosses of investigative product (IP), 200 mg belumosudil QD, in the fed state over 4 periods (each lasting 3 days with a minimum washout of 2, 8, and 4 days following completion of Periods 1, 2, and 3, respectively). Subjects also will receive 9 single oral doses of itraconazole 200 mg (QD over 9 days) in Period 2; 7 single oral doses of rabeprazole 20 mg (BID over 3 days followed by QD on 1 day) in Period 3; and 9 single doses of rifampicin 600 mg (QD over 9 days) in Period 4.

A follow-up visit will take place 3 to 5 days post-final discharge.

Part 2:

The primary objective of Part 2 of this study is to determine the effect of omeprazole on the PK of a single-day twice daily (BID; every 12 hours [Q12h]) dose of belumosudil administered orally, in healthy male subjects. Part 2 consists of 2 periods.

In Period 1, subjects will receive a single dose of belumosudil, in the fed state. In Period 2, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of a proton pump inhibitor, omeprazole.

Subjects will receive a total of 4 single oral doses of IP (200 mg belumosudil, BID [Q12h] on 2 occasions) in the fed state over 2 periods (each lasting 3 days with a minimum washout of 2 days between dosing in Period 1 and the start of dosing with non-IP in Period 2). Subjects will also receive 4 single oral doses of omeprazole 20 mg (QD over 4 days) in Period 2.

A follow-up visit will take place 3 to 5 days post-final discharge.

03

Conditions studied

  • Drug-drug Interaction
  • Autoimmune Diseases
  • Fibrotic Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males
  2. Age 18 to 55 years
  3. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), (ECG) and laboratory investigations (hematology, clinical chemistry, and urinalysis)
  4. Body weight ≥50 kg
  5. of 18.0 to 32.0 kg/m\^2 or, if outside the range, considered not by the investigator
  6. Must be willing and able to communicate and participate in the whole study
  7. Must provide written
  8. Must adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  1. Subjects who had previously participated in any other study drug trial in which receipt of an IP occurred within 90 days prior to dosing. (Subjects who had previously received belumosudil in Part 1 at least 90 days prior to dosing in Part 2 were eligible to participate.)
  2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  3. Subjects with pregnant partners
  4. History of any drug or alcohol abuse in the past 2 years
  5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
  6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission
  7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  9. abnormal biochemistry, haematology or urinalysis as judged by the investigator
  10. Positive drugs of abuse test result at screening and admission
  11. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  12. Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<80 mL/min using the Cockcroft-Gault equation
  13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
  14. Subject has a history or presence of any of the following:

    • Active gastrointestinal disease requiring therapy
    • Hepatic disease and/or (ALT) or aspartate aminotransaminase (AST) >
    • Renal disease and/or serum creatinine > ULN
    • Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  15. Subjects with a history of cholecystectomy or gall stones
  16. Subject has corrected using Fridericia's formula (QTcF) intervals >450 msec at screening or admission
  17. Serious adverse reaction or serious to any drug or the formulation ; including intolerance to itraconazole, rabeprazole, and rifampicin
  18. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
  19. Donation or loss of greater than 400 mL of blood within the previous 3 months
  20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IP administration.
  21. Failure to satisfy the investigator of fitness to participate for any other reason

Subjects Agreed to the Following Restrictions During the Duration of the Study:

  1. No alcohol during the 24-hour period prior to screening and the 24-hour period prior to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1, Periods 2 to 4 and Part 2, Period 2, until discharge for each treatment period.
  2. No food or drinks containing grapefruit or cranberry from 24 hours prior to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1 Periods 2 to 4 and Part 2 Period 2, until discharge for each treatment period.
  3. No food or drinks containing caffeine or other xanthines from 24 hours prior to admission until discharge for each treatment period.
  4. No food containing poppy seeds for 48 hours prior to screening and for 24 hours prior to admission until discharge for each treatment period.
  5. No unaccustomed or strenuous exercise from the 72-hour period before the screening visit and then from 24 hours prior to admission until discharge for each treatment period.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Part 1, Period 1

    Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1

    Drug: Belumosudil

  • Experimental
    Part 1, Period 2

    Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7. Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9

    Drug: Belumosudil · Drug: Itraconazole

  • Experimental
    Part 1, Period 3

    Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3. Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4.

    Drug: Belumosudil · Drug: Rabeprazole

  • Experimental
    Part 1, Period 4

    Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9. Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10.

    Drug: Belumosudil · Drug: Rifampicin

  • Experimental
    Part 2, Period 1

    Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.

    Drug: Belumosudil

  • Experimental
    Part 2, Period 2

    Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3. Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4.

    Drug: Belumosudil · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1

    Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose

    Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose

  2. Pharmacokinetics: Cmax of KD025m1 in Part 1

    Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose

    Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose

  3. Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2

    Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose

    Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose

  4. Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2

    Area under concentration-time curve from zero hours to infinity (AUC\[0-inf\]) and from zero hours to 24 hours post-dose (AUC\[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2

    Time frame: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose

  5. Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2

    Area under concentration-time curve from zero hours to 24 hours post-dose (AUC\[0-24\]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2

    Time frame: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose

07

Results

Posted Sep 13, 2021

Participant flow

This was a single centre, non-randomised, open label, two-part study. Part 1 of the study was a 4-period sequential dose study in healthy male subjects. The estimated duration from screening to discharge from the study was approximately 10 weeks. Part 2 of the study was a 2-period sequential dose study in healthy males. The estimated duration from screening to discharge from the study was approximately 7 weeks.

Part 1 Period 1; Part 2 Period 1
Participant flow — Part 1 Period 1; Part 2 Period 1
MilestonePart 1 Belumosudil (KD025) QD DosingPart 2 Belumosudil (KD025) BID Dosing
Started3538
Completed3538
Not completed00
Part 1 Period 2; Part 2 Period 2
Participant flow — Part 1 Period 2; Part 2 Period 2
MilestonePart 1 Belumosudil (KD025) QD DosingPart 2 Belumosudil (KD025) BID Dosing
Started3538
Completed3538
Not completed00
Part 1 Period 3
Participant flow — Part 1 Period 3
MilestonePart 1 Belumosudil (KD025) QD DosingPart 2 Belumosudil (KD025) BID Dosing
Started350
Completed320
Not completed30
Withdrew: Withdrawal by subject20
Withdrew: Protocol violation10
Part 1 Period 4
Participant flow — Part 1 Period 4
MilestonePart 1 Belumosudil (KD025) QD DosingPart 2 Belumosudil (KD025) BID Dosing
Started320
Completed300
Not completed20
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPharmacokinetics: Cmax of KD025 and KD025m2 in Part 1

Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose

Time frame:
Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1
ng/mLPart 1, Period 1: Belumosudil AlonePart 1, Period 2: Belumosudil + ItraconazolePart 1, Period 3: Belumosudil + RabeprazolePart 1, Period 4: Belumosudil + Rifampicin
Parent Drug KD0251770 ± 31.32130 ± 31.0227 ± 58.4712 ± 35
KD025m2337 ± 54.7221 ± 60.823.5 ± 70.7148 ± 57.3
PrimaryPharmacokinetics: Cmax of KD025m1 in Part 1

Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose

Time frame:
Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of KD025m1 in Part 1
ng/mLPart 1, Period 1: Belumosudil AlonePart 1, Period 4: Belumosudil + Rifampicin
Pharmacokinetics: Cmax of KD025m1 in Part 123.2 ± 40.052.5 ± 34.0
PrimaryPharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2

Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose

Time frame:
Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2
ng/mLPart 2, Period 1: Belumosudil AlonePart 2, Period 2: Belumosudil + Omeprazole
Cmax--1st dose: KD0251790 ± 34.5575 ± 145.7
Cmax--2nd dose: KD0251760 ± 37.0903 ± 63.8
Cmax--1st Dose: KD025m123.8 ± 39.618.0 ± 54.6
Cmax--2nd Dose: KD025m123.6 ± 46.418.9 ± 48.7
Cmax--1st Dose: KD025m2282 ± 75.672.3 ± 166.8
Cmax--2nd Dose: KD025m2257 ± 83.9115 ± 121.8
PrimaryPharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2

Area under concentration-time curve from zero hours to infinity (AUC\[0-inf\]) and from zero hours to 24 hours post-dose (AUC\[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2

Time frame:
Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose
Reported as:
Geometric mean · (ng*h)/mL
Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2
(ng*h)/mLPart 1, Period 1: Belumosudil AlonePart 1, Period 2: Belumosudil + ItraconazolePart 1, Period 3: Belumosudil + RabeprazolePart 1, Period 4: Belumosudil + RifampicinPart 2, Period 1: Belumosudil OnlyPart 2, Period 2: Belumosudil + Omeprazole
AUC(0-inf): KD0259080 ± 33.311200 ± 38.11680 ± 65.82500 ± 34.518800 ± 37.19880 ± 59.2
AUC(0-inf): KD025m21230 ± 69.5843 ± 73.7174 ± 11.1396 ± 50.21900 ± 90.41110 ± 30.3
AUC(0-24): KD0258430 ± 30.510400 ± 35.81510 ± 60.72490 ± 34.116800 ± 36.47970 ± 58.9
AUC(0-24): KD025m21100 ± 63.7745 ± 70.7110 ± 84.0376 ± 56.71950 ± 82.3767 ± 115.3
PrimaryPharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2

Area under concentration-time curve from zero hours to 24 hours post-dose (AUC\[0-24\]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2

Time frame:
Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose
Reported as:
Geometric mean · (ng*h)/mL
Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2
(ng*h)/mLPart 1, Period 1: Belumosudil AlonePart 1, Period 4: Belumosudil + RifampicinPart 2, Period 1: Belumosudil AlonePart 2, Period 2: Belumosudil + Omeprazole
Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 275.6 ± 42.1148 ± 41.9138 ± 91.391.5 ± 76.3

Adverse events

Collected over Part 1, Period 1: 1 day Part 1, Period 2: 9 days Part 1, Period 3: 4 days Part 1, Period 4: 10 days Part 2, Period 1: 1 day Part 2, Period 2: 4 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1, Period 1: Belumosudil Only0/35 (0%)0/35 (0%)6/35 (17.1%)
Part 1, Period 2: Belumosudil + Itraconazole0/35 (0%)1/35 (2.9%)9/35 (25.7%)
Part 1, Period 3: Belumosudil +Rabeprazole0/33 (0%)0/33 (0%)6/33 (18.2%)
Part 1, Period 4: Belumosudil + Rifampicin0/32 (0%)0/32 (0%)8/32 (25%)
Part 2, Period 1: Belumosudil Only0/38 (0%)0/38 (0%)9/38 (23.7%)
Part 2, Period 2: Belumosudil + Omeprazole0/38 (0%)0/38 (0%)5/38 (13.2%)
Most frequent serious events
Most frequent serious events
EventPart 1, Period 1: Belumosudil OnlyPart 1, Period 2: Belumosudil + ItraconazolePart 1, Period 3: Belumosudil +RabeprazolePart 1, Period 4: Belumosudil + RifampicinPart 2, Period 1: Belumosudil OnlyPart 2, Period 2: Belumosudil + Omeprazole
Ankle fractureInjury, poisoning and procedural complications0/351/350/330/320/380/38
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPart 1, Period 1: Belumosudil OnlyPart 1, Period 2: Belumosudil + ItraconazolePart 1, Period 3: Belumosudil +RabeprazolePart 1, Period 4: Belumosudil + RifampicinPart 2, Period 1: Belumosudil OnlyPart 2, Period 2: Belumosudil + Omeprazole
HeadacheNervous system disorders1/351/351/333/326/381/38
Abdominal distensionGastrointestinal disorders3/350/350/330/320/380/38
NasopharyngitisInfections and infestations0/350/350/330/320/383/38
SomnolenceNervous system disorders0/352/350/331/320/380/38
Back painMusculoskeletal and connective tissue disorders0/352/350/330/320/380/38
FatigueGeneral disorders0/350/351/331/320/380/38
Back injuryInjury, poisoning and procedural complications0/350/350/331/320/380/38
LacerationInjury, poisoning and procedural complications0/350/350/331/320/380/38
Seasonal allergyImmune system disorders0/351/350/331/320/380/38
NeutropeniaBlood and lymphatic system disorders0/350/350/331/320/380/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects Part 1: KD025 QD DosingAll Subjects in Part 2: KD025 BID DosingTotal
Mean37.0 ± 11.832.6 ± 10.634.7 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects Part 1: KD025 QD DosingAll Subjects in Part 2: KD025 BID DosingTotal
Female000
Male353873
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Subjects Part 1: KD025 QD DosingAll Subjects in Part 2: KD025 BID DosingTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American415
White283563
More than one race000
Unknown or Not Reported112
BMI (body mass index)
BMI (body mass index)(kg/m^2)All Subjects Part 1: KD025 QD DosingAll Subjects in Part 2: KD025 BID DosingTotal
Mean26.81 ± 3.0025.94 ± 3.3626.36 ± 3.20
08

Study locations

1 site
  • Quotient Sciences Ltd
    Ruddington, Nottingham NG11 6JS, United Kingdom
09

References and documents

Publications

  • Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Jul;11(7):795-806. doi: 10.1002/cpdd.1082. Epub 2022 Mar 1. PubMed 35230741 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2019, 9 months.

Results were first posted in Sep 2021, 2 years 7 months after primary completion.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 9 months is below that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2018
First posted
May 21, 2018
StartActual
Apr 9, 2018
Primary completionActual
Feb 8, 2019
CompletionActual
Feb 8, 2019
Results first posted
Sep 13, 2021
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03530995
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 21, 2018
Start date
Apr 9, 2018
Primary completion
Feb 8, 2019
Completion
Feb 8, 2019
Results posted
Sep 13, 2021
Last update
May 25, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion